EGFR activating mutations in human NSCLC correlates to positive Gefitinib (EGFR kinase inhibitor) responsiveness, thus deficiency in TLR4 in humans may further activate this pathway [47,48]. Here, EGFR is linked to non-small cell lung carcinoma.